Waters Expands Mass Spectrometry Boundaries with Introduction of Next-Generation, Upgradeable SYNAPT Platform

Waters Corporation today launched the Waters^® SYNAPT™ MS system, a next-generation quadrupole orthogonal acceleration, time-of-flight (oa-Tof) mass spectrometry (MS) platform. SYNAPT MS is a key part of Waters' strategy to enhance the quality and productivity of life science and drug discovery and development workflows.

Additionally, the SYNAPT MS system is the only platform which provides an upgrade pathway to the SYNAPT High Definition MS™ (HDMS™) system, uniquely enabling researchers to analyze samples differentiated by size, shape and charge, as well as mass, ultimately providing new capabilities that can help them meet and exceed future requirements.

“Confident sample identification, detailed characterization and increased productivity are primary requirements for intelligent mass spectrometry-based solutions in key biomedical applications such as proteomics, metabonomic profiling, biomarker discovery/validation and pharmaceutical R&D,” said Brian W. Smith, Vice President, Mass Spectrometry Operations for the Waters Division. “The new SYNAPT MS meets these demands through application specific system solutions designed to help our customers accelerate and improve the quality of laboratory analysis with the goal of advancing research and reducing time-to-market.”

SYNAPT MS is a central component of Waters' system level solutions - combining ACQUITY UltraPerformance LC^® (UPLC^®) separations, Exact Mass MSE data acquisition and ‘chemically intelligent’ MassLynx™ Informatics - designed to generate high quality, comprehensive data from complex biological samples, maximize confidence in results and enable scientists to make better informed decisions.

SYNAPT MS Systems also offer unparalleled versatility and flexibility. For example, the MALDI-enabled SYNAPT MS system enables researchers to perform MALDI imaging studies, primarily to determine the spatial localization of drugs, metabolites and peptides in biological tissues with high specificity and sensitivity. This can enable greater numbers of candidates to be evaluated in the drug discovery phase, leading to more rigorous selection of compounds for ongoing development.

”A unique aspect of the SYNAPT MS System is that it is ‘HDMS-ready.’ Our customers will be able to upgrade their systems to incorporate the unique High Definition MS capabilities when they require more powerful solutions to meet their future goals, effectively future-proofing their laboratories,” added Smith.